CRNX - Crinetics Pharmaceuticals, Inc.
About Crinetics Pharmaceuticals, Inc. (https://www.crinetics.com)
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| R. Scott Struthers | Founder, President, Chief Executive Officer & Director | 1962 | $1,187,855 USD |
| Tobin C. Schilke | Chief Financial Officer | 1975 | $1,022,423 USD |
| Stephen F. Betz | Co-Founder & Chief Scientific Officer | 1966 | $755,150 USD |
| Jeff E. Knight | Chief Development & Operating Officer | 1972 | $714,970 USD |
| Alan S. Krasner | Chief Endocrinologist | 1963 | $653,924 USD |
| Adriana Cabre | Chief Human Resources Officer | – | – |
| Chris Robillard | Chief Business Officer | – | – |
| Garlan Adams | Chief Legal Officer & Corporate Secretary | – | – |
| Gayathri Diwakar | Senior Director of Investor Relations | – | – |
| Kea Lingo | Chief Information Officer | – | – |
| Kevin Capps | Head of Intellectual Property | – | – |
| Robert Cuddihy | Senior Vice President of Medical Affairs | – | – |